Provided by Tiger Trade Technology Pte. Ltd.

Akebia Therapeutics

1.02
0.0000
Post-market: 1.00-0.0200-1.96%18:28 EDT
Volume:2.32M
Turnover:2.36M
Market Cap:273.24M
PE:-13.12
High:1.05
Open:1.01
Low:1.00
Close:1.02
52wk High:4.08
52wk Low:0.8750
Shares:267.88M
Float Shares:259.80M
Volume Ratio:0.23
T/O Rate:0.89%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.0777
EPS(LYR):-0.0208
ROE:-78.96%
ROA:2.02%
PB:9.98
PE(LYR):-49.08

Loading ...

Akebia Therapeutics Earnings Call: Vafseo Drives Transition

TIPRANKS
·
May 20

Akebia Therapeutics Balances Vafseo Momentum With Headwinds

TIPRANKS
·
May 09

Akebia Q1 revenue falls, net income misses analyst estimates on higher expenses

Reuters
·
May 07

Akebia Q1 FY26 turns to net loss of $9.1 million; revenue falls to $53.5 million

Reuters
·
May 07

Akebia Therapeutics Q1 EPS $(0.03), Inline, Sales $53.544M Beat $51.668M Estimate

Benzinga
·
May 07

Akebia Therapeutics Q1 Revenue USD 53.5 Million VS. Ibes Estimate USD 51.7 Million

THOMSON REUTERS
·
May 07

Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights

GlobeNewswire
·
May 07

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 07

Akebia Therapeutics Inc expected to post a loss of 3 cents a share - Earnings Preview

Reuters
·
May 05

Akebia grants new hires options for 208,800 shares at $1.38 each

Reuters
·
May 05

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
May 05

Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology

GlobeNewswire
·
May 04

Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights

GlobeNewswire
·
May 01

Akebia Therapeutics announces annual shareholder meeting via webcast

Reuters
·
Apr 29

Akebia Therapeutics (AKBA) Gets a Buy from Piper Sandler

TIPRANKS
·
Apr 24

Akebia Therapeutics announces annual shareholder meeting via webcast

Reuters
·
Apr 16

Akebia doses first participants in Phase 1 trial of AKB-9090 for acute kidney injury

Reuters
·
Apr 13

Akebia Therapeutics Inc - Akb-097 to Enter Phase 2 Basket Trial in Rare Kidney Diseases in Second Half of 2026

THOMSON REUTERS
·
Apr 13

Akebia Therapeutics Inc - Top Line Data From Phase 1 Trial Expected in Early 2027

THOMSON REUTERS
·
Apr 13

Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium

GlobeNewswire
·
Apr 07